Eli Lilly and Co - Company Profile
Powered by 
All the data and insights you need on Eli Lilly and Co in one report.
$295
- Save hours of research time and resources with
our up-to-date Eli Lilly and Co Strategy Report
- Understand Eli Lilly and Co position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, autoimmune disorders, men's health, and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, the Middle East, Africa and Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
Headquarters
United States of America
Address
Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr, Indianapolis, 46285-0001
Website
www.lilly.com
Telephone
1 317 2762000
No of Employees
43,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LLY (NYSE)
Revenue (2022)
$34.1B
19.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-16.1%
(2022 vs 2021)
Market Cap*
$714.6B
Net Profit Margin (2022)
XYZ
-29.8%
(2022 vs 2021)
* As of and is in US$
Eli Lilly and Co premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | Humalog |
| Human Pharmaceutical | Humulin |
| Endocrinology Products | Humatrope |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In March, Eli Lilly Japan K.K entered into an alliance agreement with Nippon Shinyaku to deliver pirtobrutinib. |
| 2024 | Plans/Strategy | In March, the company announced its plans to launch Mounjaro, a diabetes and weight loss drug, in India. |
| 2024 | Contracts/Agreements | In January, the company entered into an agreement with Isomorphic Labs to identify small molecule therapeutics against multiple targets. |
Competitor Comparison
| Key Parameters | Eli Lilly and Co | Johnson & Johnson | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | United States of America |
| City | Indianapolis | New Brunswick | Basel | Kenilworth | New York |
| State/Province | Indiana | New Jersey | - | New Jersey | New York |
| No. of Employees | 43,000 | 131,900 | 103,605 | 72,000 | 88,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David A. Ricks | Chairman; President; Chief Executive Officer | Executive Board | 2017 | 55 |
| Anat Ashkenazi | Executive Vice President; Chief Financial Officer | Senior Management | 2021 | 50 |
| Alonzo Weems | Chief Ethics and Compliance Officer; Executive Vice President - Enterprise Risk Management | Senior Management | 2021 | 52 |
| Daniel M. Skovronsky, M.D., Ph.D. | President - Lilly Research Laboratories; Chief Scientific and Medical Officer; Executive Vice President | Senior Management | 2021 | 49 |
| Diogo Rau | Chief Information and Digital Officer; Executive Vice President | Senior Management | 2021 | 48 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward